Insulin Human
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
INSULIN HUMAN: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin human is the standard replacement therapy for diabetes mellitus (endogenous insulin deficiency). The TxGNN model's top-ranked new-indication prediction is Autoimmune Oophoritis (score 99.84%), but this candidate has no clinical trials, no supporting literature, and no mechanistic rationale for therapeutic benefit — the evidence assessment itself flags it as a likely knowledge-graph comorbidity artifact rather than a genuine repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes Mellitus (insulin replacement therapy) — not itemized in this evidence pack; Germany/regulatory license data unavailable |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Germany Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in this evidence pack). Based on general pharmacological knowledge, insulin human replaces or supplements endogenous insulin to regulate glucose metabolism; its efficacy in diabetes mellitus is well established.
The proposed mechanistic link to autoimmune oophoritis is that both conditions can co-occur within autoimmune polyglandular syndrome (Type 1 diabetes plus autoimmune ovarian failure share an autoimmune predisposition). However, this is a comorbidity association, not evidence that insulin has any direct therapeutic effect on ovarian autoimmune tissue destruction. The evidence assessment explicitly characterizes this prediction as "knowledge-graph relational noise" rather than a plausible pharmacological hypothesis — insulin's glucose-lowering mechanism has no established pathway relevant to halting or reversing autoimmune oophoritis.
Reviewing the full set of 10 TxGNN predictions for this drug reinforces this conclusion: most (ranks 1, 2, 3, 5, 6, 7, 8, 10) are explicitly annotated by the evidence layer as comorbidity artifacts or even direction-reversed associations (e.g., insulin injection is a known cause of localized lipodystrophy, not a treatment for it). The two exceptions — thiamine-responsive dysfunction syndrome (rank 4) and pancreatic agenesis (rank 9) — reflect insulin's well-established role in managing secondary diabetes that arises from these genetic syndromes, which is existing standard clinical practice rather than a novel repurposing discovery.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
No authorization records are available in this evidence pack. Market status is recorded as 未上市 (Not marketed) with 0 total licenses, so no product/dosage-form table can be generated.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all unavailable in this evidence pack; TFDA label warnings/contraindications are flagged as a Blocking data gap that prevents formal S1 safety review.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (autoimmune oophoritis) has no clinical, literature, or mechanistic support and is explicitly identified by the evidence assessment as a likely knowledge-graph artifact driven by shared autoimmune comorbidity rather than a genuine pharmacological signal. Combined with a Blocking-severity gap in TFDA safety labeling and a High-severity gap in mechanism-of-action data, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA/EMA package insert data (warnings, contraindications) to clear the Blocking data gap and enable S1 safety screening
- Confirmed mechanism-of-action documentation for insulin human (DrugBank API query)
- If autoimmune oophoritis is pursued further: dedicated mechanistic or preclinical studies evaluating insulin/insulin-signaling pathways in ovarian autoimmune tissue — none currently exist
- Re-evaluate whether ranks 4 (thiamine-responsive dysfunction syndrome) and 9 (pancreatic agenesis) should instead be reclassified as "existing standard-of-care" rather than novel repurposing candidates, since insulin is already used clinically for secondary diabetes in both syndromes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.